Editorial: Community and clinical pharmacy services in type 2 diabetes care, volume II

Diabetes mellitus is a leading noncommunicable disease, with global cases rising from 108 million in 1980 to 476 million in 2017. Prevalence among adults doubled to 8.5% by 2014.Diabetes causes 1.4 million deaths annually, driving significant health, social, and economic burdens worldwide (1). Its management extends beyond glycemic control to include cardiovascular risk reduction, complication prevention, and sustained patient engagement.Type 2 diabetes and cardiovascular disease are interconnected conditions within a cardiometabolic continuum, driven by shared biological mechanisms. Newer therapies like SGLT2 inhibitors, GLP-1 receptor agonists, and tirzepatide improve cardiorenal outcomes, but disparities in access and response remain. Integrated, equitable care models are vital for effective, personalized treatment (2). Pharmacists and nurses play increasingly critical roles in multidisciplinary care, particularly in community and transitional settings where continuity and adherence remain major challenges. This Research Topic, Community and clinical pharmacy services in type 2 diabetes care: Volume II, brings together important contributions that examine the clinical effectiveness, implementation quality, and professional capacity underlying integrated diabetes care models. Implementation fidelity represents a key determinant of intervention effectiveness (3). In an implementation study by Qinqin Sun et al., of 3,351 adults aged ≥65 years, fidelity varied (mean 0.64, SD 0.19; range 0.28-0.94), and higher fidelity was associated with lower HbA1c (adjusted β -0.38 per 0.10-unit increase, 95% CI -0.47 to -0.29; p < 0.001), with a graded quartile pattern 7.89% (95% CI 7.78-8.00) vs 7.16% (95% CI 7.04-7.28); p for trend < 0.001, alongside lower systolic blood pressure (-5.10 mmHg, 95% CI -7.20 to -3.00), lower LDL cholesterol (-6.50 mg/dL, 95% CI -9.10 to -3.90), reduced hospitalization (IRR 0.61, 95% CI 0.51-0.73; p < 0.001), and lower odds of hypoglycemic events (OR 0.78, 95% CI 0.72-0.84; p < 0.001).These findings highlight that structured nursing-led assessments can deliver meaningful clinical benefits when implemented consistently, emphasizing the importance of implementation quality and workforce preparedness.Pharmacist-integrated care models represent another promising strategy for strengthening diabetes management (4). A study by Nan Gao et al., titled Construction and effectiveness of a pharmacist-involved diabetes management model between tertiary hospitals and community under the hierarchical medical system, enrolled 210 patients and evaluated a pharmacistinvolved collaborative care model over 12 months. HbA1c, the primary endpoint, decreased in the intervention group, with values declining from 7.70 ± 2.19% at baseline and reaching 6.50 and were three times more likely to achieve treatment goals than controls (5).Professional competency among frontline providers is equally essential for effective diabetes care (6). The cross-sectional study by Xuefen Lan, involving 1,911 community nurses, reported poor insulin injection knowledge in 47.7% of participants, while poor attitude and poor practice were uncommon (3.7% and 2.5%, respectively); familiarity with clinical guidelines and insulin injection training were significant predictors of knowledge, attitude, and practice (all p < 0.05).Training exposure and familiarity with clinical guidelines were significantly associated with improved knowledge, attitude, and practice (7). These findings underscore the importance of targeted professional education to ensure safe and effective insulin administration as diabetes care increasingly shifts toward community settings.Beyond care delivery structures, advances in therapeutic stratification are also critical for improving outcomes (8). The review article, New approach to optimize therapy in type 2 diabetes mellitus: the importance of subclassification, highlights the heterogeneity of T2DM and notes that patients with recently diagnosed disease may be classified into seven pathophysiologically distinct subgroups, emphasizing that cardiovascular disease represents a major complication and that stratified classification may support more precise and individualized therapeutic approaches. By aligning pharmacological strategies with underlying disease mechanisms, subclassification offers a pathway toward more personalized and effective treatment.